The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SELISARC: A Spanish Sarcoma Group (GEIS) phase I/II trial of selinexor plus gemcitabine in selected sarcoma subtypes—Results of the phase I part.
 
Javier Martin Broto
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Antonio Casado
Consulting or Advisory Role - EISAI; EISAI; Merck Sharp & Dohme; PharmaMar; Roche
Research Funding - Pharmamar (Inst)
Travel, Accommodations, Expenses - Lilly; PharmaMar; Pharmamar; Roche
Other Relationship - Lilly (Inst)
 
David Moura
Honoraria - Tecnofarma
Research Funding - Eisai (Inst); Immix BioPharma (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Pfizer; PharmaMar
 
Luis Ortega
No Relationships to Disclose
 
Andres Redondo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; PharmaMar
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar
 
Daniel Bernabeu
No Relationships to Disclose
 
Javier Martinez-Trufero
Consulting or Advisory Role - Boehringer Ingelheim Spain; Deciphera; Eisai; PharmaMar; Qinlock; Qinlock
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Merck; PharmaMar
 
Claudia Valverde
No Relationships to Disclose
 
Antonio Gutierrez
Consulting or Advisory Role - Abbvie; AstraZeneca Spain; Incyte; Janssen; Takeda
Speakers' Bureau - Abbvie; AstraZeneca Spain; Janssen; Takeda
 
Jose Lucinio Mondaza-Hernandez
Research Funding - Karyopharm Therapeutics (Inst); Lixte Biotechnology (Inst); Pharmamar-zeltia (Inst)
 
Aránzazu Manzano
Consulting or Advisory Role - Grunenthal
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Leo Pharma; MSD; PharmaMar; ROVI; Sanofi
Research Funding - AstraZeneca (Inst)
 
Gloria Marquina
No Relationships to Disclose
 
Nadia Hindi
Honoraria - PharmaMar; Tecnofarma
Consulting or Advisory Role - GlaxoSmithKline; PharmaMar
Research Funding - Adaptimmune (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Pfizer (Inst); CEBIOTEX (Inst); Deciphera (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar